Published in AAPS J on June 02, 2006
Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. AAPS J (2011) 1.06
Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing. Sci Rep (2016) 0.76
Preformulation studies of Zidovudine derivatives: Acid dissociation constants, differential scanning calorimetry, thermogravimetry, x-ray powder diffractometry and aqueous stability studies. Sci Pharm (2011) 0.75
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
Development of validated stability-indicating assay methods--critical review. J Pharm Biomed Anal (2002) 3.37
What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res (2000) 2.42
A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal Chem (2000) 1.33
Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev (1990) 1.26
Profiling drug-like properties in discovery research. Curr Opin Chem Biol (2003) 1.22
Stabilization of pharmaceuticals to oxidative degradation. Pharm Dev Technol (2002) 1.11
Solubility principles and practices for parenteral drug dosage form development. PDA J Pharm Sci Technol (1997) 1.10
Trends in solubility of polymorphs. J Pharm Sci (2005) 1.09
Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev (2004) 1.08
Formulation and stability testing of photolabile drugs. Int J Pharm (2001) 1.03
Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv Drug Deliv Rev (2001) 1.03
Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J Pharm Sci (2001) 1.02
High throughput physicochemical profiling for drug discovery. J Pharm Sci (2001) 0.94
Prediction of precipitation-induced phlebitis: a statistical validation of an in vitro model. J Pharm Sci (2003) 0.90
ICH guidance in practice: establishment of inherent stability of secnidazole and development of a validated stability-indicating high-performance liquid chromatographic assay method. J Pharm Biomed Anal (2004) 0.88
Effect of pH on injection phlebitis. J Pharm Sci (1995) 0.85
Medium-throughput pKa screening pharmaceuticals by pressure-assisted capillary electrophoresis. Electrophoresis (2001) 0.83
General pharmaceutics--the new physical pharmacy. J Pharm Sci (2003) 0.80
Predictive strategy for the rapid structure elucidation of drug degradants. J Pharm Biomed Anal (1996) 0.79
Automated analytical systems for drug development studies. I--A system for the determination of drug stability. J Pharm Biomed Anal (1994) 0.79
New screening method for the determination of stability of pharmaceuticals. Int J Pharm (2004) 0.78
An automated workstation for forced degradation of active pharmaceutical ingredients. J Pharm Sci (2002) 0.78
A novel hPepT1 stably transfected cell line: establishing a correlation between expression and function. Mol Pharm (2005) 0.98
Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1/Madin-Darby canine kidney clones and Caco-2 cells. J Pharmacol Exp Ther (2005) 0.94
Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. J Pharm Sci (2010) 0.85
Application of lipid-based formulations in drug discovery. J Med Chem (2012) 0.83
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem (2014) 0.83
Utility of gastric-retained alginate gels to modulate pharmacokinetic profiles in rats. J Pharm Sci (2013) 0.79
Toward Independence: Resubmission Rate of Unfunded National Heart, Lung, and Blood Institute R01 Research Grant Applications Among Early Stage Investigators. Acad Med (2016) 0.78
Expression of multiple drug resistance conferring proteins in normal Chinese and Caucasian small and large intestinal tissue samples. Mol Pharm (2005) 0.75
Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: a novel HCV NS3 protease inhibitor. J Pharm Sci (2014) 0.75
Assessing the risk of pH-dependent absorption for new molecular entities: a novel in vitro dissolution test, physicochemical analysis, and risk assessment strategy. Mol Pharm (2013) 0.75
Utility of in situ sodium alginate/karaya gum gels to facilitate gastric retention in rodents. Int J Pharm (2012) 0.75
Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38α inhibitor. Bioorg Med Chem Lett (2013) 0.75